A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study

被引：0
|
作者：
Prebet, Thomas [1 ,2 ]
Delaunay, Jacques [3 ]
Wattel, Eric [4 ]
Braun, Thorsten [5 ]
Cony-Makhoul, Pascale [6 ]
Dimicoli, Sophie [7 ]
Wickenhauser, Stefan [8 ]
Lejeune, Julie [9 ]
Chevret, Sylvie [10 ]
Chermat, Fatiha [11 ]
Fenaux, Pierre [2 ,12 ,13 ]
Vey, Norbert [14 ]
机构：
[1] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA
[2] Grp Francophone Myelodysplasies, Paris, France
[3] Nantes Univ Hosp, Dept Hematol, Nantes, France
[4] Univ Lyon 1, F-69365 Lyon, France
[5] CHU Avicenne, Hematol Clin, Bobigny, France
[6] Ctr Hosp Annecy Genevois, Dept Hematol, Metz, France
[7] CHU Bordeaux, Serv Hematol, Pessac, France
[8] CH Nimes, Nimes, France
[9] Hop St Louis, AP HP, Paris, France
[10] Stat St Louis Hosp, Paris, France
[11] Hop St Louis, GFM, Paris, France
[12] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France
[13] Univ Paris 08, Hop Avicenne, Serv Hematol Clin, Bobigny, France
[14] Inst J Paoli I Calmettes, Hematol, F-13009 Marseille, France
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
    Garcia-Manero, Guillermo
    Fenaux, Pierre
    Al-Kali, Aref
    Baer, Maria R.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    Gaidano, Gianluca
    Scott, Bart L.
    Greenberg, Peter L.
    Platzbecker, Uwe
    Steensma, David P.
    Kambhampati, Suman
    Kreuzer, Karl-Anton
    Godley, Lucy A.
    Collins, Robert
    Atallah, Ehab
    Wilhelm, Francois
    Wilhelm, Isabelle E.
    Azarnia, Nozar
    Maniar, Manoj
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [32] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [33] A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
    Desikan, Sai Prasad Prasad
    Montalban-Bravo, Guillermo
    Ohanian, Maro
    Daver, Naval
    Yilmaz, Musa
    Konopleva, Marina
    Kadia, Tapan M.
    Venugopal, Sangeetha
    Schneider, Heather
    Chien, Kelly S.
    Kanagal-Shamanna, Rashmi
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138 : 3704 - +
  • [34] RANDOMIZED PHASE 2 STUDY OF GUADECITABINE IN PATIENTS WITH HMA-NAIVE HIGHER RISK MYELODYSPLASTIC SYNDROMES (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Savona, M. R.
    Garcia-Manero, G.
    Roboz, G. J.
    Walsh, K. J.
    Kropf, P. L.
    Issa, J. P.
    O'Connell, C. L.
    Tibes, R.
    Yee, K. W. L.
    Stock, W.
    Lunin, S.
    Berdeja, J. G.
    Naim, S.
    Hao, Y.
    Azab, M.
    Kantarjian, H.
    LEUKEMIA RESEARCH, 2017, 55 : S40 - S41
  • [35] Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
    Sekeres, Mikkael A.
    Othus, Megan
    List, Alan F.
    Odenike, Olatoyosi
    Stone, Richard M.
    Gore, Steven D.
    Litzow, Mark R.
    Buckstein, Rena
    Fang, Min
    Roulston, Diane
    Bloomfield, Clara D.
    Moseley, Anna
    Nazha, Aziz
    Zhang, Yanming
    Velasco, Mario R.
    Gaur, Rakesh
    Atallah, Ehab
    Attar, Eyal C.
    Cook, Elina K.
    Cull, Alyssa H.
    Rauh, Michael J.
    Appelbaum, Frederick R.
    Erba, Harry P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) : 2745 - +
  • [36] Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study
    Sasaki, Koji
    Jabbour, Elias
    Bravo, Guillermo Montalban
    Short, Nicholas J.
    Kanagal-Shamanna, Rashmi
    Kadia, Tapan M.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Cortes, Jorge E.
    Ravandi, Farhad
    Alvarado, Yesid
    Chien, Kelly S.
    Yang, Hui
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [37] Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy
    Lee, Sangmin
    Desai, Pinkal
    Edirisinghe, Bianca
    Pianello, Samantha
    Curcio, Tania
    Samuel, Michael
    Ritchie, Ellen K.
    Roboz, Gail J.
    LEUKEMIA & LYMPHOMA, 2021, 62 (02) : 498 - 500
  • [38] INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs) Study design informed by subgroup analyses of ONTIME.
    Garcia-Manero, Guillermo
    Al-Kali, Aref
    Baer, Maria R.
    Robor, Gail J.
    Platzbecker, Uwe
    Kambhampati, Suman
    Godley, Lucy A.
    Collins, Robert
    Shammo, Jamile M.
    Santini, Valeria
    Raza, Azra
    Silverman, Lewis R.
    Azarnia, Nozar
    Fruchtman, Steven M.
    Snyder, Barbara R.
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM
    Robin, M.
    Porcher, R.
    Ades, L.
    Raffoux, E.
    Michallet, M.
    Francois, S.
    Cahn, J-Y
    Delmer, A.
    Wattel, E.
    Vigouroux, S.
    Bay, J-O
    Cornillon, J.
    Huynh, A.
    Nguyen, S.
    Rubio, M-T
    Vincent, L.
    Maillard, N.
    Charbonnier, A.
    de latour, R. P.
    Reman, O.
    Dombret, H.
    Fenaux, P.
    Socie, G.
    LEUKEMIA, 2015, 29 (07) : 1496 - 1501
  • [40] HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM
    M Robin
    R Porcher
    L Adès
    E Raffoux
    M Michallet
    S François
    J-Y Cahn
    A Delmer
    E Wattel
    S Vigouroux
    J-O Bay
    J Cornillon
    A Huynh
    S Nguyen
    M-T Rubio
    L Vincent
    N Maillard
    A Charbonnier
    R P de Latour
    O Reman
    H Dombret
    P Fenaux
    G Socié
    Leukemia, 2015, 29 : 1496 - 1501
12345